Cazzato Gerardo, Colagrande Anna, Ingravallo Giuseppe, Lettini Teresa, Filoni Angela, Ambrogio Francesca, Bonamonte Domenico, Dellino Miriam, Lupo Carmelo, Casatta Nadia, Resta Leonardo, Maiorano Eugenio, Cascardi Eliano, Marzullo Andrea
Section of Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.
Section of Dermatology, "Vito Fazzi" Hospital, 73100 Lecce, Italy.
J Clin Med. 2022 Nov 24;11(23):6936. doi: 10.3390/jcm11236936.
Background: In recent years, great research interest has been directed to the diagnostic, therapeutic and marker role of Preferentially expressed Antigen in Melanoma (PRAME) in the setting of various human neoplasms. Although it has been extensively studied mainly in the differential diagnosis setting of melanocytic pigmented lesions, still very few papers have analyzed the usefulness or otherwise of PRAME in the context of other non-melanoma skin cancers (NMSC). (2) Methods: In this paper, we report the data of our experience of 21 cases of sebaceous carcinoma (SC) classified in the three WHO grade and collected in the period between January 2005 and 31 October 2022, on which immunostaining for PRAME was performed; Non-parametric Mann−Whitney test for non-normally distributed values was performed. A comparison was made of the means between the three study groups (grade I, II and III). A value of p ≤ 0.05 was set as statistically significant (3) Results: Only seven cases (33.3%) were positive with an immunoscore of 2+/3+ for intensity and 1+/2+ for percentage cells positivity, while 14 cases (66.6%) were totally or nearly totally negative for PRAME with a few of sebaceous-like cells positive with an immunoscore of 1+. Eight cases of SC grade I were immunostaining for PRAME, a level of the cytoplasm of foci of sebaceous differentiation with a significant statical value (p < 0.0001) with respect to ten cases of SC grade II; furthermore, the eight cases of grade I were positive for PRAME in the same areas respect the 3 cases of SC grade III (p = 0.0303). There were no statistical significance between the 10 cases of grade II and 3 cases of grade III (p = 0.2028); (4) Conclusions: PRAME not seems to add particular information in the case of histopathological diagnostics of SC where other markers, including adipophylline, can be quite indicative. It seems, on the other hand, that PRAME can be useful in the subclassification setting of sebaceous carcinoma in grades I−II−III according to the directives of the latest WHO 2018, highlighting the foci of mature sebaceous differentiation most present in grades 1−2 and almost completely absent in grade 3 of the SC.
近年来，黑色素瘤优先表达抗原（PRAME）在各种人类肿瘤中的诊断、治疗及标志物作用引发了极大的研究兴趣。尽管其主要在黑素细胞色素沉着性病变的鉴别诊断中得到广泛研究，但在其他非黑色素瘤皮肤癌（NMSC）背景下分析PRAME有用性的论文仍非常少。（2）方法：在本文中，我们报告了2005年1月至2022年10月31日期间收集的21例按世界卫生组织三级分类的皮脂腺癌（SC）病例的数据，对这些病例进行了PRAME免疫染色；对非正态分布值进行非参数曼-惠特尼检验。比较了三个研究组（I级、II级和III级）之间的均值。设定p≤0.05为具有统计学意义。（3）结果：仅7例（33.3%）呈阳性，强度免疫评分为2+/3+，细胞阳性率免疫评分为1+/2+，而14例（66.6%）PRAME完全或几乎完全阴性，少数皮脂腺样细胞呈阳性，免疫评分为1+。8例I级SC进行了PRAME免疫染色，皮脂腺分化灶的细胞质水平与10例II级SC相比具有显著统计学意义（p<0.0001）；此外，I级的8例在相同区域PRAME呈阳性，与3例III级SC相比（p = 0.0303）。10例II级和3例III级之间无统计学意义（p = 0.2028）；（4）结论：在SC的组织病理学诊断中，PRAME似乎并未增加特别的信息，在这种情况下其他标志物，包括脂联素，可能颇具指示性。另一方面，根据世界卫生组织2018年最新指南，PRAME似乎在I-II-III级皮脂腺癌的亚分类中有用，突出了成熟皮脂腺分化灶在SC的1-2级中最为常见而在3级中几乎完全缺失的情况。
